Cyclophosphamide and topotecan are standard anticancer drugs
used to treat patients with Ewing’s sarcoma and neuroblastoma.
Despite this therapy, however, in some patients the cancer
returns or persists. In this study, researchers are evaluating
the safety and effectiveness of adding the drug bevacizumab to
cyclophosphamide and topotecan therapy in children and
adolescents with Ewing’s sarcoma or neuroblastoma that has
returned or persists despite standard therapy. Bevacizumab works
by inhibiting the formation of blood vessels that tumors need to
grow and spread. It is given intravenously (by vein). It is
already approved for the treatment of several other types of
cancer, but its use in this study is considered investigational.
This study is coordinated by POETIC, a consortium of several
U.S. hospitals that conducts clinical trials for children with
cancer.